Terazosin and energy metabolism in Parkinson's
Treatments studied
Part of Brain & nervous system clinical trials.
This trial tests whether terazosin, a drug for blood pressure and enlarged prostate, can improve energy use in brain cells affected by Parkinson's. If it works, it might slow disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of Parkinson's disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests several experimental drugs at once to find new treatments for Parkinson's disease. If you have Parkinson's and take medication, you may be able to join and help speed up research.
This study tests a new tablet called ENERGI-F705 to see if it helps reduce Parkinson's disease symptoms and is safe to take. You'll need to have had Parkinson's for at least 2 years and be on standard Parkinson's medications.
This study tests an experimental insomnia drug called dimdazenil in people with Parkinson's disease who also have trouble sleeping. It aims to see if the drug can improve sleep without causing new side effects.
This study tests whether an experimental medicine called SUL-238 can improve energy levels in the brain cells of people with early, untreated Parkinson's. It uses a special type of MRI to see if the medicine affects brain energy.
This trial tests a new gene therapy called ZR001 for people with Parkinson's disease. It involves a one-time surgery to inject the therapy into the brain, and researchers want to see if it's safe and can help improve movement symptoms.
This study tests an experimental drug, MTX325, in people with Parkinson's disease. The goal is to see if it is safe and how the body processes it, which may lead to new treatment options.
Hear when a new Parkinson's Disease (PD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.